Ach was... Wer denn bitte nicht?
|
|
As at November 5, 2020, we had 62,678,613 common shares issued and outstanding, as well as 326,410 stock options, 173,000 deferred share units and 47,232,366 share purchase warrants outstanding.
As at September 30, 2020 we had $21.8 million of cash and cash equivalents.
Nach Q4 sollten es um die 26 Mio$ sein.
Warrants as at August 5, 2020
Warrants | Exercise Price | |||||||||
# | $ | Expiry date | ||||||||
December 2015 registered direct offering | 2,331,000 | 7.10 | December 13, 2020 | |||||||
September 2019 registered direct offering | 3,325,000 | 1.65 | September 24, 2024 | |||||||
February 2020 Financing | 2,608,696 | 1.20 | August 21, 2025 | |||||||
February 2020 Financing | 243,478 | 1.61719 | February 19, 2025 | |||||||
July 2020 Financing | 26,666,666 | 0.45 | July 7, 2025 | |||||||
July 2020 Financing | 1,866,667 | 0.5625 | July 1, 2025 | |||||||
August 2020 Financing | 9,320,907 | 0.47 | February 5, 2026 | |||||||
August 2020 Financing | 869,952 | 0.7040625 | August 3, 2025 | |||||||
47,232,366 |
Termine 2020:
Q1 ---- Ende PIP 01 (Kindrstudie)
10. März --- Ende der Serie A Warrants
24. März ----- Die 1,65$ September 2019 Warrants dürfen ausgeübt werden
1 April -------Beneficial Ownership Determination Date/ Record Date for Voting
6.April ------- Finale Ergebnisse PIP 01 (positive Results In Dose-finding)
1. Mai ------- Ende der 945T 4,7$ Warrants
15. Mai ------- Annual Meeting
8 Juni -------- Registrierung der 2019 und 2020 Warrants (Verkauf über den Markt zulässig)
25 Juni -------- Megapharm Distribution Agreement (ISRAEL AND THE PALESTINE)
7 Juli ----------- CLOSING OF $12 MILLION PUBLIC OFFERING
5.August -------- CLOSING OF $7 MILLION PUBLIC OFFERING
16.Nov ------------- Novo Lizenzdeal (Kompl. Rechte Mac US)
7. Dez. ------------- Consilient Health Ltd (Verkaufsrechte Mac AGHD)
13. Dez ---------- Ende der 2,33 Mio 7,1$ Warrants
Termine 2021
25. Jan ----------- NASDAQ 1$ Regel (Ende erste 180 Tage)
Q1. -------- geplant Anfang PIP 02
März ------------ Möglich: Hauptversammlung
April ---------------- Möglich: RS (Kann erst nach Zustimmung der Aktionäre)
Ende Juli ----------- NASDAQ 1$ Regel (Ende zweite 180 Tage) mögliches Delisting
Q2 2022------- geplant Ende PIP 02
min Q3 2023 ------------- AEterna mögliche EMA/FDA Zulassung pediatric US / EU
Q1 2024 --------------- Ende Kohle ohne Pipeline :-)))))
Novo (US)
Commercial Milestone Payments
a) cumulative Net Sales of Product in a Calendar Year reaching twenty five million dollars: Commercialization payment of four million dollars (US$4,000,000);
b) cumulative Net Sales of Product in a Calendar Year reaching fifty million dollars: Commercialization payment of ten million dollars (US$10,000,000);
c) cumulative Net Sales of Product in a Calendar Year reaching onehundred million dollars: Commercialization payment of twenty million dollars (US$20,000,000);
d) cumulative Net Sales of Product in a Calendar Year reaching two hundred million dollars: Commercialization payment of forty million dollars (US$40,000,000); and
e) cumulative Net Sales of Product in a Calendar Year reaching five hundred million dollars: Commercialization payment of one hundred million dollars (US$100,000,000).
Consilient Health Ltd (EU)
10.2.2 Commercial Milestones:
(i) Upon annual Net Sales first reaching Euro 4,000,000 (four million): Euro 250,000 (€ two hundred fifty thousand);
(ii) Upon annual Net Sales first reaching Euro 6,000,000 (six million): Euro 400,000 (€ four hundred thousand);
(iii) Upon annual Net Sales first reaching Euro 8,000,000 (eight million): Euro 600,000 (€ six hundred thousand); and
(iv) Upon completion of annual Net Sales first reaching Euro 10,000,000 (ten million): Euro 1,000,000 (€ one million).
In US stellen sich die Versicherungen der Kostenübernahme immer noch quer. Die EU wird sich dabei nicht anders verhalten.
Der nächste Step, die Verhandlungen mit den Versicherungen.
M.E. werden sie herbe Abschläge in Kauf nehmen müssen. Die Consilient Meilensteinzahlungen sprechen eine ganz klare Sprache.
Ist natürlich auch ein Argument, das Novo nicht bei den EU Rechten zugeschlagen hat.
Monetization of non-strategic assets
Opportunities for the Company to monetize non-strategic assets include preclinical work done on AEZS-120, a prostate cancer vaccine and preclinical and clinical work done on AEZS-104 (perifosine) and our small molecule kinase inhibitor program.
Doch, Zopt steht immer noch zum Verkauf!
|
Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
25 | 17.117 | Aeterna nach dem Split | Heron | Hbit | 25.11.23 10:08 | |
9 | 13.769 | AEZS vs. KERX | Gropius | paioneer | 03.09.22 18:22 | |
19 | Wie geht's jetzt weiter mit Aeterna Zentaris? | Ebi52 | Bullish_Hope | 03.08.22 00:11 | ||
21 | 7.680 | Aeterna Zentaris Inc. | Heron | Heron | 30.09.21 23:37 | |
2 | 62 | AEterna Zentaris (AEZS)- Reboundkandidat?? | Vollzeittrader | marroni | 25.04.21 13:13 |